In this case, all-transretinoic acid (ATRA) treatment could increase the expression level of CD38 and reduce the expression of complement inhibitory proteins, CD55 and CD59, in MM cells, indicating that ATRA enhances the activity of Daratumumab (40). This evidence concerns the gene CD38 and Miyoshi myopathy.